Prot #ACE-CL-208: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Project: Research project

Project Details

StatusActive
Effective start/end date5/15/16 → 5/15/25

Funding

  • INC Research, LLC ((OE) Prot #ACE-CL-208 // (OE) Prot #ACE-CL-208)
  • Acerta Pharma B.V. ((OE) Prot #ACE-CL-208 // (OE) Prot #ACE-CL-208)